Skip to main content
. 2023 Mar 7;19(3):440–451. doi: 10.1007/s12024-023-00578-6

Table 3.

PEP regimen and alternative treatment regimen recommended by CDC

Population PEP regimen(preferred) Alternative regimen
Adults and adolescents (≥ 13 years) with normal renal function (Cr CL ≥ 60 mL/min)

Tenofovir disoproxil fumarate 300 mg once daily or emtricitabine 200 mg once daily

 + 

Dolutegravir 50 mg once daily

or

Raltegravir 400 mg twice daily

Tenofovir disoproxil fumarate 300 mg once daily or emtricitabine 200 mg once daily

 + 

Darunavir 800 mg (as two, 400-mg tablets) once daily and ritonavirb 100 mg once daily

Adults and adolescents (≥ 13 years) with renal dysfunction (Cr CL ≤ 59 mL/min)

Zidovudine and Lamivudine, with both doses adjusted to degree of renal function

 + 

Raltegravir 400 mg twice daily

 + 

Dolutegravir 50 mg once daily or Raltegravir 400 mg twice daily

Zidovudine and Lamivudine, with both doses adjusted to degree of renal function

 + 

Darunavir 800 mg (as two 400-mg tablets) once daily

 + 

Ritonavirb 100 mg once daily

Children aged 2–12 years Tenofovir DF, emtricitabine, and Raltegravir, with each drug dosed to age and weight

Zidovudine and Lamivudine

 + 

Raltegravir or lopinavir/ritonavir

 + 

Raltegravir (lopinavir/ritonavir dosed to age and weight)

Cr CL, creatinine clearance